India, July 3 -- India plans to substantially increase its production-linked incentives for the pharmaceutical industry. The new PLI scheme will cover additional molecules that are used to produce critical starting materials, pharma intermediates, and APIs. As an API manufacturer, what will this step do for your business in the long term?

The new PLI scheme is a well-timed and very welcome development. As India's first vertically integrated virtual API company, HRV has much to gain. We run an asset-light business that focuses on bringing a unique portfolio of products while consolidating underutilised capacities of USFDA/EUGMP-compliant Indian manufacturers.

By broadening the pool of eligible molecules under PLI, we are able to commerci...